Kula Investments’s Amicus Therapeutics FOLD Stock Holding History

Kula Investments’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-51,399	Closed	-$628K	–	699
2022 Q4	$628K	Buy	+51,399	New	+$579K	0.18%	154

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Kula Investments's FOLD Position: Q1 2023 in Review

Kula Investments sold out of Amicus Therapeutics (FOLD) in Q1 2023, closing a stake of 51,399 shares — an estimated $628K sold.

Kula Investments first reported a position in FOLD in Q4 2022 and held it in 1 quarter. The position peaked at $628K in Q4 2022. 226 funds tracked by Wall St. Rank hold FOLD as of Q1 2023.

Kula Investments reported no remaining Amicus Therapeutics position as of Q1 2023 after selling out during the quarter.
Kula Investments sold 51,399 Amicus Therapeutics shares in Q1 2023, an estimated $628K.
Kula Investments first reported a position in Amicus Therapeutics in Q4 2022 and held it in 1 quarter.
Kula Investments's Amicus Therapeutics position peaked at $628K in Q4 2022.
226 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2023.

Based on Kula Investments's 13F filing for Q1 2023, filed 15 May 2023.